Stay ahead of the curve with our experts’ breakdown of this month’s market shifts and the insights shaping our portfolio positioning.
Fast reading:
- We are seeing a desynchronisation in the performance of the global economy and in the fourth quarter results season.
- We are more constructive on duration following the moves in fixed income markets in January. Longer duration bonds may not be overly cheap, but they are a lot more attractive today.
- This month, we made a number of modifications to our flagship portfolios in response to evolving market conditions.
- Within equities, we increased our exposure to the Medtech sector and reduced the allocation to pharmaceuticals with deteriorating pipelines.
- Within fixed income, we made the decision to increase duration moving to a more neutral duration standpoint from a strategic point of view.
A desynchronisation in global growthEquity markets have had a respectable start to the year with the world index returning almost 5.5% in euro terms year-to-date. Economic momentum remains strong in the US, which is helpful, but the earnings season has been the primary driver of the move in equity indices. However, the move in equity markets has become narrow again. If we look at an equal weighted world index it is just about in positive territory in euro terms. Thus far this year the performance of the global economy has been desynchronised. The US continues to defy the forecasters and is accelerating again. The euro area is stalling and China, while growing at close to 5.0%, is skirting with deflation and a depressed property market. Inflation data is more mixed and interest rate expectations in the developed world have deteriorated. This has flown through equity markets. Of the 11 sector groupings, four are down year-to-date. The interest rate-sensitive sectors (Property and Utilities) and the sectors sensitive to Chinese growth (Materials and Energy). The top performing sectors are IT and Communication Services, and it is the earnings outcome that is delivering their strength. The large caps in these sectors have delivered better results than expected as sales momentum was maintained in the fourth quarter. The only other sector to out-perform this year is Healthcare. Some of this is due to recovery from relatively poor performance in Q4 2023 but results from the sector have also given a boost. We are still travelling through the fourth quarter results season, and we are seeing desynchronisation here as well. In the US, profits for the quarter are 7% higher than forecast. In the euro area, earnings performance is not as good, results are just in line with forecasts. Some of this is due to sectoral mix (higher weight in Commodity sectors and small exposure to the ‘new economy’) but a moribund local economy and struggling China is also weighing on the region. The worrying feature we see is that in the US, more companies are cutting guidance than raising it. We generally do not see this outside of recession periods which casts doubts over the current forecasts. This is why we are cautious on equity markets; profit expectations need to come down. | Bernard Swords, |
Increasing portfolio durationWe are more constructive on duration following the moves in fixed income markets in January. Longer duration bonds may not be overly cheap, but they are a lot more attractive today. Three factors which we consider when looking at bond markets today are:
As we cover in more detail below, we have increased portfolio duration – and the moves to do so bring us to a neutral duration stance from a strategy perspective. Within our portfolios, we have a higher allocation to high-quality investment grade corporate bonds relative to the Bloomberg Euro Aggregate Index. Corporate bonds as we know offer a higher yield relative to government bonds to compensate investors for that additional corporate risk. Corporate bonds also typically have a lower duration profile relative to government bonds. Hence, as we have a higher allocation to corporate bonds that provide higher yield, but have lower duration, our natural neutral duration stance will be slightly lower than an index with less corporate bond exposures such as the Bloomberg Euro Aggregate Index. | Elizabeth Geoghegan, |
Equity and fixed income allocation changesThis month, we made a number of modifications to our flagship portfolios within both the equity and fixed income allocations in response to evolving market conditions. The most significant change to our portfolio construction comes from our fixed income allocation. We have been incrementally increasing the duration of the portfolios since Q4 of last year, moving away from the shorter maturity profile which we successfully employed through 2022 and early 2023. At our latest Asset Allocation meeting, we made the decision to increase duration once more moving to a more neutral duration standpoint from a strategic point of view. We increased the weighted maturity profile of our fixed income portfolios, using longer duration European government bonds. From a strategy perspective, we consider the portfolios neutral duration. However, relative to the Barclays Euro Aggregate Index, we retain a slightly lower weighted duration. This is because our government bond maturity profile is balanced by an overweight or higher allocation to corporate bonds which have a higher yield and lower maturity profile relative to the overall investment grade fixed income universe. Within equities, we continue to favour a defensive bias with overweight positions in sectors such as Healthcare and Industrials. The only change within the positioning is a rotation within the mix of our Healthcare exposure – increasing our exposure to the Medtech sector and reducing the allocation to pharmaceuticals with deteriorating pipelines. There are three key drivers of this rotation:
| Sarah Quirke, |
This is a marketing communication.